Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
NCT03225144 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 360
Last updated 2026-05-22
Summary
Background:
Neurodegenerative disorders can lead to problems in movement or memory. Some can cause abnormal proteins to build up in brain cells. Researchers want to understand whether these diseases have related causes or risk factors.
Objective:
To test people with movement or thinking and memory problems to see if they are eligible for research studies.
Eligibility:
People ages 18 and older with a neurodegenerative disorder associated with accumulation of TDP-43 or Tau proteins
Design:
Participants will have a screening visit. This may take place over 2-3 days. Tests include:
Medical history
Physical exam
Questions about behavior and mood
Tests of memory, attention, concentration, and thinking
Movement measurement. The speed at which participants can stand up from a chair, tap their finger and foot, and walk a short distance will be measured. Some movements will be videotaped. They will be videotaped while they speak and read a paragraph.
Blood tests. This might include genetic testing.
Lung and breathing tests
MRI. They will lie on a table that slides into a cylinder that takes pictures of the body. Some participants will get a dye through IV.
Electromyography. A thin needle will be inserted into the muscles to measure electrical signals.
Nerve tests. Small electrodes on the skin record muscle and nerve activity.
A small piece of skin may be removed.
A skin or blood sample may be taken to create stem cells.
Optional lumbar puncture. A needle will be inserted into the space between the bones of the back to collect fluid.
If participants are not eligible for current studies, they may be contacted in the future.
...
Conditions
- Frontotemporal Dementia
- Amyotrophic Lateral Sclerosis
- Progressive Supranuclear Palsy
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
lead NIH
Principal Investigators
-
Justin Y Kwan, M.D. · National Institute of Neurological Disorders and Stroke (NINDS)
Eligibility
- Min Age
- 18 Years
- Max Age
- 110 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-10-11
- Primary Completion
- 2027-10-30
- Completion
- 2027-10-30
Countries
- United States
Study Locations
More Related Trials
-
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
NCT00159198 ·Status: TERMINATED
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
NCT02649985 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems
NCT00413621 ·Status: COMPLETED
-
Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
NCT04680130 ·Status: ENROLLING_BY_INVITATION
-
Stratification of Presymptomatic Amyotrophic Lateral Sclerosis: the Development of Novel Imaging Biomarkers
NCT05358431 ·Status: RECRUITING ·Phase: NA
-
Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
NCT01353430 ·Status: RECRUITING
-
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
NCT06254469 ·Status: RECRUITING ·Phase: PHASE3
-
Diagnosing Frontotemporal Lobar Degeneration
NCT02964637 ·Status: RECRUITING
-
Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II
NCT02317250 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology
NCT01886820 ·Status: UNKNOWN ·Phase: PHASE3
-
Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer's Disease
NCT06224920 ·Status: COMPLETED
-
Neurodegenerative Diseases Registry
NCT04472130 ·Status: UNKNOWN
-
Imaging Blood Brain Imaging Dysfunction in Parkinson's Disease
NCT02605161 ·Status: COMPLETED
-
The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)
NCT03702816 ·Status: TERMINATED ·Phase: PHASE2
-
[18F]MC225-PET in Neurodegenerative Disease
NCT05853471 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Assess Fibrin in Brains With AD/ADRD
NCT05336695 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Multimodal Markers of Neurodegenerative Disorders at Presymptomatic Stages
NCT06516016 ·Status: NOT_YET_RECRUITING
-
Early Detection of Mild Cognitive Impairment in Individual Patients
NCT00243451 ·Status: COMPLETED
-
A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease
NCT06057909 ·Status: RECRUITING
-
FluoroAv45 Imaging Research-in Alzheimer's Disease
NCT01325259 ·Status: COMPLETED ·Phase: PHASE2
-
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
NCT06999434 ·Status: RECRUITING ·Phase: PHASE1
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
NCT05456503 ·Status: RECRUITING ·Phase: PHASE3
-
Brain Imaging in Elderly People and Individuals With Alzheimer's Disease
NCT00001917 ·Status: COMPLETED
-
4 Repeat Tauopathy Neuroimaging Initiative
NCT01804452 ·Status: COMPLETED
-
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
NCT01680588 ·Status: UNKNOWN ·Phase: PHASE2